drugset
drugset / Trial / NCT02027025

Study of SPARC1103 in Subjects With Spasticity

NCT02027025 ↗

Phase 2 Completed 142 enrolled Sun Pharma Advanced Research Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

Study of SPARC1103 in subjects with spasticity

Timeline

Start
2014-04-21
Primary completion
2017-04-28
Completion
2017-04-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator SPARC1103 Unknown — —

Indications

No indication recorded.